Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Pfizer, Arvinas breast cancer therapy approved by FDA

Digest more
Top News
Overview
Highlights
 · 11h · on MSN
US FDA approves Pfizer, Arvinas' breast cancer drug
By Padmanabhan Ananthan May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast cancer drug for patients with an advanced form of the disease whose tumors carry a specific genetic mutation.

Continue reading

Fierce Pharma · 14h
FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype
 · 17h
Pfizer, Arvinas breast cancer therapy approved by the FDA
 · 1d
AstraZeneca falls as FDA advisers reject breast cancer drug use
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 1.9% to 13,688p after the US regulator's advisory panel declined to back its camizestrant treatment in a key breast cancer setting.

Continue reading

 · 1d
AstraZeneca’s Breast-Cancer Candidate Drug Loses FDA Panel Vote
 · 1d
FDA panel votes against backing AstraZeneca's breast cancer drug
 · 1d
AstraZenca shares fall as US advisory panel votes against breast cancer drug
In a separate decision the ODAC voted seven-to-one in favour of the company’s prostate cancer drug Truqap, or capivasertib, combined with abiraterone and androgen deprivation therapy.

Continue reading

 · 1d
AstraZeneca Shares Weaken After FDA Panel Rejects Camizestrant
 · 17h
Arvinas, Pfizer Get FDA Approval for Breast Cancer Treatment
1don MSN

Pfizer Just Scored a Win That Wall Street Can't Ignore

The pharmaceutical giant just extended the lifespan of one of its top drugs.
1d

Pfizer hoping for earlier Elrexfio use in RRMM after Phase III trial

Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug showed benefit as a second-line therapy in a Phase III trial. In the MagnetisMM-5 study (NCT05020236),
Las Vegas Sun
3d

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the U.
Fierce Pharma
4d

Pfizer settles with 2 generic Vyndamax makers in latest twist to ATTR market: analysts

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, eleventh-hour settlements with two of the three generic drugmakers | Eleventh-hour settlements with two of the three generic drugmakers involved could bode well for both Pfizer and its ATTR competitor BridgeBio,
3don MSN

Should You Buy, Sell, or Hold Pfizer at $27?

The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question mark.
1mon

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.
PolitiFact
4d

As tick season drags longer, Pfizer hopes to release a Lyme disease vaccine in 2027

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne
3don MSN

Pfizer secures deals to keep heart drug free of generic rivals until 2031

April 28 (Reuters) - Pfizer said on Tuesday it has settled patent disputes with three generic drugmakers over its blockbuster heart drug Vyndamax, effectively extending its patent protection until 2031 and delaying cheaper copies from entering the market.
1d

Goldman Sachs resets Pfizer stock forecast

Pfizer has spent the past few years trying to convince investors that its post-pandemic business can stand on its own, and Goldman Sachs appears to be asking for more proof before getting more bullish on the stock.

Related topics

Arvinas
Vyndamax
Coinbase
  • Privacy
  • Terms